Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Spotlight Innovation Inc (STLT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 5,281
  • Shares Outstanding, K 34,290
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,730 K
  • 36-Month Beta -1.85
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.61
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.17
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/24/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1136 +33.80%
on 02/12/18
0.2300 -33.91%
on 01/18/18
-0.0526 (-25.71%)
since 01/16/18
3-Month
0.0826 +84.02%
on 11/17/17
0.2700 -43.70%
on 12/08/17
+0.0545 (+55.90%)
since 11/16/17
52-Week
0.0800 +90.00%
on 10/24/17
0.5800 -73.79%
on 03/14/17
-0.3580 (-70.20%)
since 02/16/17

Most Recent Stories

More News
Venodol Roll-on, Spotlight Innovation's New Analgesic Product, Now Available at Amazon.com

Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company subsidiary Caretta Therapeutics' new over-the-counter chronic...

STLT : 0.1520 (-1.30%)
Spotlight Innovation Forms Corporate Partnership with University of Iowa Athletics to Promote New Chronic Pain Relief Product "Venodol"

URBANDALE, IA--(Marketwired - Sep 27, 2017) - Spotlight Innovation Inc. (OTCQB: STLT) today announced that it has formed a corporate partnership with University of Iowa Athletics that will provide ongoing...

STLT : 0.1520 (-1.30%)
Spotlight Innovation Forms Corporate Partnership with University of Iowa Athletics to Promote New Chronic Pain Relief Product "Venodol"

URBANDALE, IA--(Marketwired - Sep 27, 2017) - Spotlight Innovation Inc. (OTCQB: STLT) today announced that it has formed a corporate partnership with University of Iowa Athletics that will provide ongoing...

STLT : 0.1520 (-1.30%)
Spotlight Innovation Enters into Sponsored Research Agreement with Indiana University to Develop New Therapies for Spinal Muscular Atrophy

URBANDALE, Iowa , Aug. 16, 2017 /PRNewswire/ --  Spotlight Innovation Inc. (OTCQB: STLT) today announced that the Company has entered into a Sponsored Research Agreement with Indiana University...

STLT : 0.1520 (-1.30%)
New Chronic Pain Relief Product "Venodol" Now Available for Pre-order at Venodol.com

Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that its subsidiary Caretta Therapeutics' new over-the-counter chronic...

STLT : 0.1520 (-1.30%)
New Chronic Pain Relief Product "Venodol" Now Available for Pre-order at Venodol.com

URBANDALE, Iowa , Aug. 7, 2017 /PRNewswire/ --  Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that its subsidiary...

STLT : 0.1520 (-1.30%)
Spotlight Innovation Subsidiary Caretta Therapeutics Engages Public Relations Firm TransMedia Group

Spotlight Innovation Inc. (OTCQB: STLT) today announced that its subsidiary Caretta Therapeutics, LLC, has engaged TransMedia Group to provide public relations support for Venodol, a new over-the-counter,...

STLT : 0.1520 (-1.30%)
Spotlight Innovation Enters into Sponsored Research Agreement to Develop New Therapies for Spinal Muscular Atrophy

URBANDALE, Iowa , June 30, 2017 /PRNewswire/ --  Spotlight Innovation Inc. (OTCQB: STLT) today announced that the Company has entered into a Sponsored Research Agreement with Brigham and Women's...

STLT : 0.1520 (-1.30%)
Spotlight Innovation to Present Poster at the Cure SMA 2017 Annual SMA Conference

Spotlight Innovation Inc. (OTCQB: STLT) today announced that the Company will participate in a family-friendly research poster session at the Cure SMA 2017 Annual SMA Conference, which the Company is supporting...

STLT : 0.1520 (-1.30%)
Spotlight Innovation to Present Poster at the Cure SMA 2017 Annual SMA Conference

URBANDALE, Iowa , June 22, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT) today announced that the Company will participate in a family-friendly research poster session at the Cure...

STLT : 0.1520 (-1.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Key Turning Points

2nd Resistance Point 0.1700
1st Resistance Point 0.1610
Last Price 0.1520
1st Support Level 0.1370
2nd Support Level 0.1220

See More

52-Week High 0.5800
Fibonacci 61.8% 0.3890
Fibonacci 50% 0.3300
Fibonacci 38.2% 0.2710
Last Price 0.1520
52-Week Low 0.0800

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.